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CSF or rhIL-3 to induce cord blood CFU-GM colony formation when incubated with isolated CD34+ progenitor cells (13) . rhIL-6, however, has been the only hematopoietic growth factor that has been demonstrated to induce in vivo neonatal rat thrombocytosis ( 1 I).
Several hematopoietic growth factors have been identified to regulate the kinetics of early hematopoietic stem cells. SCF, IL-6, and G-CSF have all been demonstrated to enhance IL-3-dependent proliferation of early hematopoietic progenitor cells by shortening the Go period of dormant stem cells (14) (15) (16) . Recently, a novel hematopoietic cytokine, IL-11, has been identified from a medium conditioned by primate BM stromal cells (PU-34) (17) . IL-1 I has also been demonstrated to act synergistically with IL-3 to induce the proliferation of early hematopoietic stem cells by shortening their Go dormant period (18) . Schibler et al. (19) demonstrated that IL-11 in vitro induces a dose-related increase in the cycling of fetal progenitor cells (erythroid blast-forming unit, CFU-GM, and CFU-erythroid, myeloid, megakarocytic). We hypothesize that rhIL-l l may also have profound modulating effects on in vivo neonatal rat hematopoiesis and host defense. In the present study, we determined the in rivo effects of rhIL-11 on neonatal rat hematopoiesis both alone and in combination with a lineage-specific CSF (rhG-CSF) and examined its modulating effect on the mortality rate during experimental group B streptococcal sepsis.
MATERIALS AND METHODS
rlzIL-11. rhIL-11 was kindly supplied by Genetics Institute (Cambridge, MA). It was produced in Esclzerichia coli and purified to homogeneity. A biologic activity of 1.5 x lo6 U/mg was determined by stimulation of the T10 cell line assay. The absence of measurable endotoxin contamination was demonstrated by the Limulus amebocyte lysate assay. rhIL-11 was diluted in PBS/.O I % HSA before injection for in vivo studies at a dose ranging from 0 to 250 &kg animal body weight.
rlzG-CSF. rhG-CSF, kindly provided by Jeff Andresen (Amgen, Thousand Oaks, CA), was also prepared from E, coli to 95% purity before formulation in 0.025% HSA. The absence of measurable endotoxin contamination was demonstrated by the Limulus amebocyte lysate assay. Five pg/kg purified rhG-CSF were used (diluted with PBS, pH 7.4). A biologic activity of 2 x lo3 U/mg was determined by granulocyte colony formation on human nonadherent bone marrow cells in semisolid media.
Animal inoczilation. This study used litters of neonatal albino Sprague-Dawley rats (Bantin-Kingman Laboratories, Fremont, CA) 1 2 4 h old (6-8 g ). Mothers of the litters were received 1 wk before delivery and housed at the California State University, Fullerton, vivarium. Approval for this study was granted by the Animal Use Committee. The animals were maintained at constant room temperature, with water and rodent feed (Purina Chow) ad libitlrm. The site of injection was washed with Betadine solution (povidone-iodine, lo%, Purdue Frederick, Norwalk, CT) and swabbed with 70% alcohol before each inoculation of growth factor. Animals were initially given daily injections of rhIL-11 for 14 d at concentrations of 1, 10, 100, and 250 rg/kg body weight. Once a dose-response relationship was demonstrated, 250 pglkg was chosen as the rhIL-11 concentration in the following combination experiments. Animals were then given injections of either rhIL-11, rhG-CSF (5 pglkg), or simultaneous rhIL-11 and rhG-CSF for 14 d, PBS/HSA for 7 d followed by rhG-CSF for 7 d, or of rhIL-11 for 7 d followed by rhG-CSF for 7 d. Intraperitoneal injections of 0.100 mL were performed with a sterile tuberculin syringe fitted with a 27.5-gauge needle. Control animals received 0.100-mL injections of PBS/O.Ol% HSA.
Q~tanriJication of circzilating platelets, nezctrophils, and BM myeloid pools. Twenty pL of free-flowing blood were collected by nicking the jugular vein with a sterile 25-gauge needle. Samples were electronically counted (Serano-Baker Diagnostics, Allentown, PA) to determine platelet and white blood cell counts; blood smears were prepared and stained with Wright stain, and a 100-to 200-cell differential was performed. Femoral BM was removed surgically and aseptically on d 14, and neutrophil BM pools (NSP + NPP) were determined as previously described by CFU-GM colony formation. BM was collected as previously described (10) . After suspension in Hanks' balanced salt solution (Gibco Laboratories, Grand Island, NY), cells were cultured in methylcellulose media containing 0.8% methylcellulose, FCS (30%), BSA (I%), and mercaptoethanol M) (Terry Fox Laboratories, Vancouver, BC, Canada). A total of 2 x lo5 cells were stimulated by murine-spleen-cell-conditioned medium (1%) (Terry Fox Laboratories) and erythropoietin (4 U/mL) (Amgen). Cell suspensions were plated in triplicate in 10 X 35-mm tissue culture dishes (Nunc, Denmark) and incubated at 5% COz, 37"C, in a high humidity atmosphere. Cultures were evaluated at 10 d with aggregates of >50 cells considered "colonies." Myeloid colonies were plucked and stained, and specific lineage was confirmed. This agarose culture, however, was not optimal for CFU-MEG determination.
CFUproliferative rate. Thymidine suicide was used to evaluate the proliferative rates of CFU-GM as previously described (10) . Light-density bone marrow mononuclear cells from neonatal rats were placed in 50-mL centrifuge tubes, nonradioactive thymidine and methyl-3H-thymidine containing 0.1 mCi (sp act, 75 Ci/mmol, ICN Radiochemicals, Irvine, CA) were added, tubes were incubated for 20 min, and thymidine uptake was terminated by adding excess nonradioactive thymidine in ice-cold a-minimum essential medium with FCS. The cell suspensions were then washed twice with cold thymidine media, and plated in methylcellulose as described above. Colonies were enumerated after 10 d of culture in a 5% COz incubator at 37°C. The thymidine suicide rate was determined by subtracting the average number of colonies formed per plate by cells exposed to 'Hthymidine from the average number of colonies per plate formed by cells exposed to nonradioactive thymidine, divided by the average colonies per plate from cells exposed to nonradioactive thymidine.
Organism. Group B streptococcus (type 111, Noms, kindly provided by Dr. Gerald Fisher, Bethesda, MD) was isolated from an infected neonate and serotyped by the precipitin method using rabbit anti-sera. The organism was grown in Todd-Hewitt broth to logarithmic phase and then aliquoted and stored at -70°C until use. Aliquots were thawed and allowed to grow to maximum-phase growth in fresh Todd-Hewitt broth. Organisms were then sedimented by centrifugation and washed three times in sterile PBS. Concentration of bacteria was determined by OD at 620 nm, and a suspension of 2.5 x 10' organisms/g body weightlo. 100 mL was prepared for injection.
Experimental sepsis. After receiving rhIL-1 1, rhIL-1 1 + rhG-CSF sequentially and simultaneously, rhG-CSF, PBS/HSA, or PBS/HSA/rhG-CSF for 14 d, 2.5 x 10' organisms/g of body weight of group B streptococcus was injected intrapentoneally into each group of animals. Survival was monitored for the next 120 h. Control animals received sham injections of PBS/O.Ol% HSA.
Stalistical analysis. All results are expressed as mean zk SEM of four animals or multiple runs of three to five replicates of blood or BM samples. The probability of significant differences when comparing two treated groups was determined with the use of the unpaired t test, whereas the probability of significant differences when examining multiple treatments was determined by using analysis of variance followed by the Student-NewmanKeuls multiple-range tests to define the unique subsets within the study. Statistical analyses were performed using the Biostat I IL-l l AND NEONAl 'AL HEMATOPOIESIS Lastly, we examined the prophylactic effect of 14 d of rhIL-11 alone or given sequentially or simultaneously with rhG-CSF in modulating the survival rate after inducing experimental group B streptococcal sepsis. There was a significant difference in (Fig. 7) . However, by 96 h, there was no significant difference in survival between any of the treatment groups (96 h, p = NS) (Fig. 7) . DISCUSSION 1L-l l has been found to synergize with IL-3 in supporting murine MEG colony formation and stimulating the proliferation of T-cell-dependent Ig-producing B cells (17) . In addition to the synergistic effect of IL-1 I with IL-3 to shorten the dormant Go phase of stem cells, I L I 1 has also been demonstrated to support 60 CAIRO ET AL.
the formation ofCFU-GM, CFU-GEMM, and CFU-blast colony formation from cultures of marrow cells from normal mice (1 8). Recently, IL-11 was demonstrated to enhance CFU-GEMM formation when used in combination with Steel factor and IL-3 in serum containing cultures from d-2 enriched post-5-FU mouse marrow (15) . Although IL-11 and IL-6 have similar in vitro biologic effects (i.e. shortened Go dormant stem cell phase, synergistic with IL-3 on murine CFU-MEG proliferation, induced hepatic synthesis of acute-phase reactants, and stimulation of Ig B-cell production), they are truly two distinct cytokines ( 18) .
Although total body neonatal rat concentrations of CFU-GM and NSP are significantly reduced compared with adult animals, the total concentrations of neonatal rat CFU-MEG are currently unknown (3) (4) (5) . Recently, Olson et a/. (20) demonstrated increased levels of circulating CFU-MEG in preterm and term cord blood compared with adult peripheral blood. These findings are similar to increased circulating levels of CFU-GM and CFU-GEMM in preterm and term cord blood (6, 7). Thrombocytopenia (<100000/mm3) is commonly (12%) found in preterm newborns (< 1500 g) and is associated with an increased incidence of intraventricular hemorrhage compared with those preterm infants who have no evidence of thrombocytopenia (2 1).
Although administration of rhIL-11 alone had a negligible effect in neonatal rats on the circulating hematocrit and absolute neutrophil count, it induced a significant increase in the circulating platelet count (100 and 250 pg/kg/d). rhIL-11, however, also induced a significant increase in neonatal rat BM NSP, NPP, CFU-GM, and CFU-GM proliferative rates compared with placebo-controlled animals. The increase in the BM CFU-GM proliferative rate by rhIL-11 in vivo is similar to that demonstrated by Schibler et al., in vitro (19) . However, the increase in BM myelopoietic precursors did not result in an increase in the circulating neutrophil count. It appears that secondary stimulation of committed myeloid progenitors and terminally differential myeloid cells with G-CSF is required before a peripheral response occurs.
When rhIL-11 was given both sequentially and simultaneously with rhG-CSF over a 14-d period, there was a significant increase in the circulating absolute neutrophil count during the 2nd wk of therapy compared with appropriate control-group animals. Additionally, the sequential and simultaneous administration of rhIL-11 and rhG-CSF induced a significant increase in the BM NSP over that of control animals and rhG-CSF alone. The simultaneous administration of rhIL-11 and rhG-CSF induced a significant increase in the BM NSP CFU-GM + CFU-GM proliferative rate similar to our previous studies using simultaneous rrSCF + rhG-CSF (1 2).
Although the combination of rhIL-11 and rhG-CSF induced a significant increase in the circulating absolute neutrophil count during the 2nd wk of therapy, it failed to reduce the mortality rate during experimental group B streptococcal sepsis. We have previously demonstrated that rrSCF alone or in combination with rhG-CSF, without antibiotics, reduced the mortality rate during experimental group B streptococcal sepsis. Because the combinations of rrSCF + rhG-CSF and rhIL-11 + rhG-CSF both demonstrated a significant increase in the circulating absolute neutrophil count and enhanced BM myeloid pools, other mechanisms besides augmentation of myelopoiesis may be playing a role in the difference in their prophylactic effect during experimental group B streptococcal sepsis (12) . We postulate, as we previously demonstrated (l2), that the increase in the BM mast cell pool by either rrSCF alone or in combination with rhG-CSF may play a role in enhancing neonatal rat host defense and thereby differentially reduce the mortality rate during experimental group B streptococcal sepsis. Alternatively, the differential individual and synergistic hematopoietic and host defense effects of IL-11 and SCF may also play a role in their relative ability to reduce morbidity and mortality during overwhelming bacterial infection. However, similar bacterial inoculums that induce a lower lethal dose at 24 h might benefit from IL-11 & G-CSF.
We have now demonstrated that both rhIL-11 and rhIL-6 enhance the circulating platelet count in neonatal rats (1 1). rhIL-1 1, however, either used alone or in combination with rhG-CSF, significantly induced a higher circulating platelet count compared with our previous rhIL-6 studies (1 1). Our study suggests that the in vitro effects of rhIL-11 on murine CFU-MEG proliferation also result in a significant in vivo response relative to an enhancement of the circulating platelet count. The in rivo effects of rhIL-11 on the circulating platelet count are similar to the in vivo effects of rhIL-6 (22, 23) .
In summary, we have found that 14-d administration of rhIL-11 in neonatal rats results in a significant increase in the circulating platelet count with relatively little effect on the circulating hematocrit and absolute neutrophil count. However, when rhIL-1 1 was used either sequentially or simultaneously in combination with a lineage-specific CSF (rhG-CSF), there is enhancement in the circulating absolute neutrophil count. We hypothesize that rhIL-11 has more profound effects on neonatal thrombopoiesis compared with rrSCF or lineage-specific CSF such as rhG-CSF or recombinant murine GM-CSF. However, when rhIL-11 is used in combination with lineage-specific CSF, either sequentially or simultaneously, it may have additive effects on neonatal granulopoiesis by potentially shortening the dormant stem cell phase and inducing committed progenitor proliferation. rhIL-11 may have a potential role in either preventing or ameliorating thrombocytopenia in both preterm and term newborns.
